Skip to content
Search

Latest Stories

REALITY CHECK: Side-lining community pharmacy - it’s a policy future governments will live to regret

By Graham Phillips

In the 1960s, roughly 5,000 miles of railway tracks were closed and more than 2,000 stations were axed to cut the mounting debts of the nationalised British Rail.


The name of the architect of what became known as the ‘Beeching Axe’, Dr Richard Beeching, remains associated with the mass closure of railways and the loss of many local services.

Fast forward to December 2015 when the Department of Health revealed that it was going to cut community pharmacy funding to make the National Health Service more efficient.

Shockwaves ran through the sector then and community pharmacies are feeling the impact even now, four years on.

A total of 223 pharmacies closed in the first two years and the trend continues to date.

The latest victim, Summerhill Pharmacy in Ramsgate, shut its doors for good on Saturday, February 1.

Customers of the pharmacy received text messages informing them of the closure and the need to redirect any repeat prescription orders.

A notice at the pharmacy says: “We are very sorry to announce the closure of Summerhill Pharmacy. Government cutbacks mean that we, along with Boots, Lloyds and others, can no longer afford to run some stores and we have no option but to close permanently”.

One down, 2,999 to go – of the three thousand predicted to fold up!

As it happens, Summerhill pharmacy belongs to me; we have two others in Thanet.

Meanwhile, despite government promises, GP surgeries are shutting and merging at an ever-increasing rate.

This is partly about finance but mainly because GPs are stressed, over-worked and demoralised.

Many are taking early retirement.

Unlike us, they can afford to hand back their NHS contract and live on the generous NHS pension they’ve accumulated (opportunities, of course, that we in community pharmacy are denied).

Small wonder there’s a GP recruitment crisis.

According to the Royal College of GPs we are around 16,000 GPs short and the government is now hosing money at the GP network in a belated attempt to stabilise it.

But it takes a minimum of 10 years to train a GP; there’s no chance that the Government’s strategy will achieve its ends anytime soon. Retirement continues to outpace recruitment.

Readers of Pharmacy Business will be all too well aware that community pharmacy can take a lot of pressure off GPs – approximately 30 per cent of workload – and hospitals – 8 per cent of A&E visits alone.

In Scotland and Wales, the respective NHS’ organisations are investing in community pharmacies to reduce pressure on the system.

Whereas, in stark contrast, NHS England wants to force local pharmacies, such as yours, to close.

This is being done by means of indiscriminate financial attrition.

Like you, we are not protected despite the numerous awards we have won, and the incredibly high satisfaction our patients have in our services.

Of the three largest multiples, Lloyds have sold or closed 200 branches (with more to come).

Boots plan to close at least 200 and Rowlands around 100.

What hope it there for the little guys like you and me?

So, despite the fact that Summerhill Pharmacy is the only pharmacy in the area, and despite the exceptional service we offer (the Summerhill community is a high-need community), and despite the fact we are open 100 hours per week to serve people, the pharmacy had been losing money every month.

We simply could not sustain the loss and had to close.

The local surgery, also called Summerhill, is a vulnerable surgery serving a vulnerable population.

GPs in that part of Thanet are rarer than hen’s teeth and as for GP partners? Forget it!

We take workload off the surgery on a daily basis, dealing with queries, assisting with smoking cessation and correcting the odd prescribing error.

Then there’s the saving on the drugs budget – for example suggesting a cheap, generic alternative to 300ml alemamazine syrup represcribed following a hospital in-patient stay, thereby saving the practice £300 at a stroke.

All gone.

We serve exactly the sort of disillusioned “left behind” population that politicians are so concerned about these days.

Meanwhile, in the railway world, the cost of HS2 which the government has just announced will go ahead at the eye-watering cost of £106 billion.

This is what happens when political vandalism sacrifices an infrastructure on the altar of an ideology remote from the reality of people’s everyday lives.

By the time the government realises it has wrecked the network of independent community pharmacies, it will be too late, and too expensive, to rectify.

Graham Phillips who once owned a group of 10 pharmacies now owns three. He’s also the founder of prolongevity.co.uk.

This article also appears in the March issue of Pharmacy Business.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less